cardiovascular%20disease%20prevention
CARDIOVASCULAR DISEASE PREVENTION
Cardiovascular disease (CVD) development is closely related to lifestyle characteristics and associated risk factors.
There is an overwhelming scientific evidence that lifestyle modifications and reduction of risk factors can slow the development of CVD both before and after the occurrence of a CV event.
Primary CVD prevention is aimed at the healthy population, individuals who have several CV risk factors or 1 CV risk factor at a very high level, and individuals whose risk for a CV event is high. Secondary CVD prevention is aimed at individuals with confirmed CVD.

Cardiovascular Disease Prevention Drug Information

Drug Information

Indication: 60 mg: Co-administered w/ acetylsalicylic acid (ASA) for prevention of atherothrombotic events in adult patien...

Indication: Reduction of elevated total cholesterol (total-C), LDL-C, apolipoprotein B (ApoB), total-C: HDL-C ratio trigly...

Indication: Primary hypercholesterolaemia: Administered alone or w/ an HMG-CoA reductase inhibitor (statin) indicated as a...

Indication: Adjunct to diet for patients w/ elevated total cholesterol (total-C) & LDL-cholesterol (LDL-C), apolipopro...

Indication: Adjunct to diet & maximally tolerated statin therapy in adults w/ heterozygous familial hypercholesterolem...

Indication: Adjunct to diet for patients w/ elevated total cholesterol (total-C), LDL-cholesterol (LDL-C), apolipoprotein ...

Cardin
aspirin + glycine

Indication: Transient ischaemic attacks, secondary prevention of MI. Prophylaxis against stroke, vascular occlusion & ...

Indication: Transient ischaemic attacks, secondary prevention of MI. Platelet aggregation inhibitor for prophylaxis agains...

Indication: AMI. Prevention of heart attack in certain high-risk patients; prevention of CVA after transient ischaemic att...

Indication: Adult patients suffering from MI (few days until <35 days), ischaemic stroke (7 days until <6 mth) or es...

1  /  6
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elvira Manzano, 28 Jul 2020
The efficacy and cardiovascular (CV) safety of the SGLT2* inhibitor empagliflozin vs DPP-4** inhibitors and GLP-1*** receptor agonists in real-world patients were demonstrated in two interim analyses of the EMPRISE+ study presented at ADA 2020.
Roshini Claire Anthony, 3 days ago

Patients hospitalized with mild-to-moderate COVID-19 who are on angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) for hypertension should continue these medications, according to primary results of the BRACE CORONA trial presented at ESC 2020.

Tristan Manalac, 09 Jul 2020
Left ventricular assist devices (LVADs) trigger almost immediate favourable metabolic changes in both diabetics and nondiabetics, according to a recent study.
Tristan Manalac, 04 Sep 2020
Anticoagulation therapy may be of value to patients with new-onset atrial fibrillation (AF) associated with sepsis, easing the risk of all-cause mortality and ischaemic stroke without increasing the likelihood of major bleeding, reports a study presented at the Digital 2020 Congress of the European Society of Cardiology (ESC).